Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D- CECaT): A new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma

A. Donfrancesco, G. Deb, C. Dominici, A. Angioni, M. Caniglia, L. De Sio, P. Fidani, A. Amici, L. Helson

Research output: Contribution to journalArticle

Abstract

Thirteen patients with Stage III (3 patients) or Stage IV (10 patients) neuroblastoma were treated with a new iron chelation-cytotoxic therapy regimen. Deferoxamine given for five consecutive days followed by 3 days of cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECaT) caused moderate to severe myelotoxicity. In 39 courses there were four episodes of sepsis; platelet and packed red blood cell transfusions were required in 72% and 82% of courses, respectively. Mild nausea and vomiting occurred in 52% of courses. Objective responses after two courses were observed in 12 of 13 patients. Three of four partial responses were achieved in previously treated relapsed patients, and seven of eight complete responses (four of which were surgically documented) were achieved in previously untreated patients. This cytoreduction regimen appears to be an improvement over other initial induction regimens and may be worth testing in larger populations.

Original languageEnglish
Pages (from-to)319-322
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume15
Issue number4
Publication statusPublished - 1992

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D- CECaT): A new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma'. Together they form a unique fingerprint.

  • Cite this